Vivoryon Therapeutics N.V. (VVY.AS)
- Previous Close
1.7280 - Open
1.7000 - Bid --
- Ask --
- Day's Range
1.7000 - 1.7360 - 52 Week Range
0.7800 - 6.3000 - Volume
16,407 - Avg. Volume
59,620 - Market Cap (intraday)
45.617M - Beta (5Y Monthly) 1.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7900 - Earnings Date May 21, 2025 - May 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
www.vivoryon.comRecent News: VVY.AS
View MorePerformance Overview: VVY.AS
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is AEX-Index (^AEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VVY.AS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VVY.AS
View MoreValuation Measures
Market Cap
44.94M
Enterprise Value
35.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-62.22%
Return on Equity (ttm)
-120.41%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-20.57M
Diluted EPS (ttm)
-0.7900
Balance Sheet and Cash Flow
Total Cash (mrq)
9.39M
Total Debt/Equity (mrq)
1.29%
Levered Free Cash Flow (ttm)
-12.06M